Results 51 to 60 of about 48,812 (228)

Overall survival with combined nivolumab and ipilimumab in advanced melanoma [PDF]

, 2017
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.
Schadendorf D., Rutkowski, Piotr, Ivan Marquez-Rodas, Ascierto, P.A., Schadendorf D, Rutkowski P., Dummer R, Smylie, M., Wagstaff, J., Gonzalez R, Grob, J-J., Lao, C.D., Hogg, D., C. Lance Cowey, Haanen, J., Haanen, John, Marquez-Rodas I, Dummer R., McArthur G, Linda Rollin, Guidoboni M., Hill, Andrew, Ascierto PA, Sosman J., Dirk Schadendorf, Grob JJ, Larkin J, Jonathan Cebon, Carlino MS, Carlino, M.S., Celeste Lebbé, Grob, Jean-Jacques, Rollin L., Jedd D. Wolchok, Guidoboni M, Smylie M., Postow, M.A., Hill A., Hodi F. S., Maio M., Chiarion-Sileni, V., Margaret K. Callahan, Chiarion-Sileni V, Lebbe C, Jeffrey Sosman, Schadendorf, D., Piotr Rutkowski, Rollin L, Carlino M. S., Marquez-Rodas I., Bhore, R., Ferrucci, Pier F, Cowey CL, Gonzalez, Rene, Matteo S. Carlino, Callahan M. K., Vanna Chiarion-Sileni, Hogg, David, Ferrucci, P.F., Schadendorf, Dirk, Cebon J, Hodi FS, John Wagstaff, Bechter O., Pier F. Ferrucci, Dummer, R., Maio M, John Haanen, Callahan, M.K., Smylie M, Bhore R., Dana Walker, Hill, A., Smylie, Michael, Long G. V., Andrew Hill, Cebon, J., Walker D., Long, G.V., Wagstaff, John, Lebbe C., Lebbe, C., Hogg D, Gonzalez R., Bechter O, Cowey, C Lance, McArthur G., Larkin J., Massimo Guidoboni, Christopher D. Lao, Rutkowski, P., Michele Maio, Hill A, Maio, M., Ascierto P. A., Marquez-Rodas, I., David Hogg, Michael Smylie, Cowey, C.L., Wolchok, J.D., Wolchok J. D., Callahan MK, Cebon J., Wolchok JD, Sosman J, Dummer, Reinhard, Rene Gonzalez, Gonzalez, R., Jean-Jacques Grob, F. Stephen Hodi, Postow MA, Wagstaff J., Larkin, J., McArthur, G., Sosman, J., Bhore R, Grant McArthur, Haanen J, Bechter, Oliver, Wagstaff J, Paolo A. Ascierto, Carlino, Matteo S, Chiarion-Sileni V., Georgina V. Long, Postow M. A., Walker D, Cowey C. L., Chiarion-Sileni, Vanna, James Larkin, Reinhard Dummer, Oliver Bechter, Rutkowski P, Lao, Christopher D, Walker, D., Hogg D., Guidoboni, M., Ferrucci PF, Lao C. D., Grob J. -J., Ferrucci P. F., Haanen J., Hodi, F.S., Long GV, Rafia Bhore, Wolchok, Jedd D, et al, Rollin, L., Michael A. Postow, Lao CD   +148 more
core   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita, Takeru Matsuda, Junko Mukohyama, Ryohei Sasaki, Yoshihiro Kakeji   +4 more
wiley   +1 more source

Ipilimumab and Bevacizumab in Glioblastoma [PDF]

, 2016
The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade.
T. Carter, Carter, T, K. Chester, Carter, T., Mulholland, P, P. Mulholland, H. Shaw, D. Cohn-Brown, Mulholland, P., Shawy, H, Shaw, H., Chester, K, Cohn-Brown, D, Chester, K., Cohn-Brown, D.   +14 more
core   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. [PDF]

PLoS ONE, 2018
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of ...
Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy   +6 more
doaj   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S   +8 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Tumor uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma during ipilimumab treatment

, 2019
Introduction Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly improves overall survival.
van den Eertwegh, AJM, Miedema, IHC, Vugts, DJ, Menke, C. W., Hoekstra, OS, Huisman, MC, de Gruijl, TD, Zwezerijnen, GJC, Oprea - Lager, D, Verheul, HMW   +9 more
core   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source